



**Dr. med. Dipl. biochem. Patricia Geller** Management Board Member at Limbach Gruppe SE

# Personal data

Date and place of birth:

02.03.1967 in Hanover, Germany German

## **Education**

Nationality:

**2005 – 2006** International Executive MBA at the IE Business School, Madrid, Spain

### 1994 – 2001

Qualification as specialist physician for laboratory medicine at various organizations and institutes in the UK and Germany

# 1995 - 1996

Post-doctorate at La Jolla Cancer Research Foundation, La Jolla, San Diego, USA

# 1986 - 1994

Studies of human medicine and doctorate at Medical School of Hanover University

# 1986 - 1993

Studies of biochemistry at Hanover University (graduating with master's degree)



### **Professional career**

#### 2019 - present day

#### Member of Management Board

Regional responsibility for 15 laboratories and for the business fields of laboratory medicine, clinical medicine, and pathology, as well as for strategy, innovation, business development, marketing, procurement, information security, and quality management Limbach Gruppe SE, Heidelberg, Germany

### 2015 - 2018

Head of Business Development, Strategy and Marketing Department Member of Extended Management Board Limbach Gruppe SE, Heidelberg, Germany

# 2011 - 2015

Head of Business Development Department Limbach Gruppe SE, Heidelberg, Germany

## 2009 - 2010

Senior Director Global Product Management / Molecular Diagnostics Business Field Qiagen GmbH, Hilden, Germany

#### 2007 - 2008

Director of Corporate Strategy Qiagen GmbH, Hilden, Germany

### 2004 – 2007

Business Development Manager EMEA / Molecular Diagnostics Business Unit Abbott GmbH, Wiesbaden, Germany

#### 2002 - 2004

Scientific Affairs Manager / Diagnostics Division Abbott GmbH, Wiesbaden, Germany

# <u>Memberships in statutory supervisory boards and/or in comparable domestic or foreign</u> <u>supervisory bodies of commercial enterprises</u>

Dr. med. Geller is currently not a member of any other statutory supervisory boards or comparable supervisory bodies at domestic or foreign commercial enterprises pursuant to § 125 (1) Sentence 3 AktG.